Core Viewpoint - The company has submitted a confidential F-1 registration statement to the U.S. Securities and Exchange Commission for a proposed dual listing in the U.S., which is a significant step in its global strategy and is expected to bring multiple positive impacts [1] Group 1: Global Financing and Market Expansion - The dual listing is anticipated to expand the company's global financing channels by entering one of the largest and most comprehensive capital markets, potentially attracting more long-term international investors focused on biotechnology and healthcare [1] - This move is expected to provide strong capital support for the company's future research and commercialization efforts [1] Group 2: Brand and Market Presence - Listing on NASDAQ is expected to enhance the company's international brand influence, improving its corporate image and industry recognition in global markets [1] - It will also increase opportunities for communication and collaboration with potential global partners, clients, and regulatory bodies [1] Group 3: Share Liquidity and Valuation - The establishment of a cross-market trading mechanism is likely to broaden the investor base and enhance overall share liquidity [1] - This international pricing environment is expected to better reflect the company's long-term value [1] Group 4: Governance and Compliance - Adhering to U.S. securities regulations and disclosure requirements is projected to improve the company's governance standards and operational transparency [1] - This will strengthen the company's compliance image and investor trust on a global scale [1] Group 5: Strategic Flexibility - The dual listing structure will provide the company with a richer platform for capital operations and strategic options for future international collaborations, mergers, and business expansions [1]

Core Viewpoint - The company, Huajian Medical, has proposed a dual primary listing on the NASDAQ stock market through the issuance of new ordinary shares in the form of American Depositary Shares, with a confidential F-1 registration statement submitted to the SEC on September 29, 2025. This move is part of the company's global strategic layout and is expected to bring multiple positive impacts. Group 1: Strategic Impacts - Expanding global financing channels: Entering one of the largest and most comprehensive capital markets globally is expected to attract more long-term international investors focused on biotechnology and healthcare, providing strong capital support for future R&D and commercialization [1] - Enhancing international brand influence: Listing on NASDAQ will further enhance the company's corporate image and industry recognition in international markets, increasing opportunities for communication and collaboration with global partners, clients, and regulatory bodies [1] - Increasing share liquidity and valuation potential: Establishing a cross-market trading mechanism will help expand the investor base, improve overall share liquidity, and reflect the company's long-term value in a more international pricing environment [1] - Optimizing corporate governance and transparency: Adhering to U.S. securities regulations and disclosure requirements will enhance the company's governance standards and operational transparency, strengthening its compliance image and investor trust globally [1] Group 2: Future Strategic Flexibility - Providing flexibility for future strategic advancement: The dual listing structure offers a richer capital operation platform and strategic options for potential international cooperation, mergers, and business expansion [2]